The US Food and Drug Administration (FDA) has granted orphan drug designation to Cornerstone Pharmaceuticals' CPI-613, lead Altered Energy Metabolism Directed (AEMD) drug candidate, for the treatment of myelodysplastic syndrome (MDS).
MDS is a form of cancer that occurs when the blood-forming cells in the bone marrow are damaged, which leads to low numbers of one or more type of blood cells.
In about one-third of MDS cases, the disease progresses to a rapidly growing cancer of bone marrow cells called acute myeloid leukaemia (AML). Currently no cure for MDS exists for patients with this life-threatening disease.
Robert Rodriguez, Cornerstone’s President and Chief Operating Officer, said, “Approximately 15,000 people are diagnosed with MDS in the United States each year. Treatment options for MDS patients are limited, especially for patients with relapsed or refractory disease, and are often associated with myelosuppressive side effects. We are encouraged by the lack of myelosuppression, good tolerability and signals of activity that were observed in MDS patients in the phase I trial. We look forward to expanding our experience with CPI-613 as a monotherapy in the treatment of relapsed / refractory MDS patients in the recently launched Phase II MDS clinical trial as well as the possibility of establishing CPI-613 as an alternative treatment option for this rare and devastating disease.”
Orphan drug designation is granted by the FDA to therapeutics intended to treat rare diseases that affect fewer than 200,000 individuals in the United States. The designation entitles Cornerstone Pharmaceuticals to seven years of US marketing exclusivity for CPI-613 upon regulatory approval, as well as an opportunity to apply for grant funding from the US government to defray costs of clinical trial expenses, tax credits for clinical research expenses, and a potential waiver of the FDA’s application user fee. In addition to MDS, Cornerstone Pharmaceuticals has previously received orphan drug designation for the use of CPI-613 in the treatments of AML and pancreatic carcinoma.
CPI-613 induces cancer-specific inhibition of pyruvate dehydrogenase (PDH) and alpha ketoglutarate comdehydrogenase (KGDH), key mitochondrial enzymes involved in cancer cell metabolism. Disruption of PDH and KGDH function leads to catastrophic disruption of tumor mitochondrial metabolism. As a result, tumour cells are starved of energy and biosynthetic intermediates, culminating in cell death. CPI-613 is currently being evaluated in phase I, I/II and phase II trials in hematologic malignancies and solid tumours. The results from the phase I single agent trial were presented at the 2013 American Society for Clinical Oncology (ASCO) Annual Meeting and hand-selected for inclusion in the Best of ASCO 2013 educational series.
CPI-613 is the lead drug candidate from Cornerstone's proprietary AEMD platform. Cornerstone’s AEMD drug platform disrupts biochemical alterations in the conversion of glucose to energy that occur in many types of cancer cells. These essential "bioenergetic" differences are linked to critical pathways, particularly those that support cancer cell growth and development.
Cornerstone Pharmaceuticals, Inc. is a privately held company that is committed to changing the way cancer is treated through the discovery and development of innovative therapies capitalizing on the unique metabolic processes of cancer cells.